AU2012304993B2 - Removal of contaminating viruses from AAV preparations - Google Patents

Removal of contaminating viruses from AAV preparations Download PDF

Info

Publication number
AU2012304993B2
AU2012304993B2 AU2012304993A AU2012304993A AU2012304993B2 AU 2012304993 B2 AU2012304993 B2 AU 2012304993B2 AU 2012304993 A AU2012304993 A AU 2012304993A AU 2012304993 A AU2012304993 A AU 2012304993A AU 2012304993 B2 AU2012304993 B2 AU 2012304993B2
Authority
AU
Australia
Prior art keywords
filter
virus
sample
virions
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012304993A
Other languages
English (en)
Other versions
AU2012304993A1 (en
Inventor
Wilhelmus Theodorus Johannes Maria Christiaan Hermens
James Patrick Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uniqure IP BV
Original Assignee
Uniqure IP BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47832422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012304993(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Uniqure IP BV filed Critical Uniqure IP BV
Publication of AU2012304993A1 publication Critical patent/AU2012304993A1/en
Application granted granted Critical
Publication of AU2012304993B2 publication Critical patent/AU2012304993B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06—Organic material
    • B01D71/08—Polysaccharides
    • B01D71/10—Cellulose; Modified cellulose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B01D2311/2623—Ion-Exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B01D2311/2649—Filtration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Water Supply & Treatment (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2012304993A 2011-09-08 2012-09-07 Removal of contaminating viruses from AAV preparations Ceased AU2012304993B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161532176P 2011-09-08 2011-09-08
US61/532,176 2011-09-08
EP11180594.1 2011-09-08
EP11180594 2011-09-08
PCT/NL2012/050619 WO2013036118A1 (en) 2011-09-08 2012-09-07 Removal of contaminating viruses from aav preparations

Publications (2)

Publication Number Publication Date
AU2012304993A1 AU2012304993A1 (en) 2014-03-20
AU2012304993B2 true AU2012304993B2 (en) 2017-09-14

Family

ID=47832422

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012304993A Ceased AU2012304993B2 (en) 2011-09-08 2012-09-07 Removal of contaminating viruses from AAV preparations

Country Status (19)

Country Link
US (3) US9840694B2 (enExample)
EP (3) EP3425044A1 (enExample)
JP (2) JP6198278B2 (enExample)
KR (1) KR101961347B1 (enExample)
CN (2) CN107502597A (enExample)
AU (1) AU2012304993B2 (enExample)
BR (1) BR112014005255A2 (enExample)
CA (1) CA2847604A1 (enExample)
DK (1) DK2744895T3 (enExample)
EA (1) EA027511B1 (enExample)
ES (1) ES2558168T3 (enExample)
HU (1) HUE026579T2 (enExample)
IL (1) IL231398A (enExample)
MX (1) MX349601B (enExample)
PL (1) PL2744895T3 (enExample)
PT (1) PT2744895E (enExample)
SI (1) SI2744895T1 (enExample)
WO (1) WO2013036118A1 (enExample)
ZA (1) ZA201401714B (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6198278B2 (ja) * 2011-09-08 2017-09-20 ユニキュアー アイピー ビー．ブイ． Ａａｖ調製物からの混入ウイルスの除去
WO2015060722A1 (en) 2013-10-24 2015-04-30 Uniqure Ip B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3215191B1 (en) 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
HUE046643T2 (hu) * 2014-11-28 2021-11-29 Uniqure Ip Bv DNS szennyezõdések parvovirális virionokat tartalmazó készítményben
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
AU2015370903B2 (en) 2014-12-24 2021-06-17 Uniqure Ip B.V. RNAi induced huntingtin gene suppression
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
EP3831281B1 (en) 2016-08-30 2026-02-25 The Regents of The University of California Devices and systems for biomedical targeting and delivery
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
JP7389040B2 (ja) 2018-01-17 2023-11-29 メイラジーティーエックス・ユーケー・ザ・セカンド・リミテッド 遺伝子治療のための修飾ｒＡＡＶキャプシドタンパク質
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
WO2020053258A1 (en) 2018-09-12 2020-03-19 Uniqure Ip B.V. Rnai induced c9orf72 suppression for the treatment of als/ftd
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
JP2022514112A (ja) * 2018-10-15 2022-02-09 リジェネクスバイオ インコーポレイテッド 複製欠損型ウイルスベクター及びウイルスの感染性を測定するための方法
AU2019382824A1 (en) 2018-11-19 2021-06-03 Uniqure Ip B.V. Method and means to deliver miRNA to target cells
WO2020104295A1 (en) 2018-11-19 2020-05-28 Uniqure Ip B.V. Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3
AU2019385638A1 (en) 2018-11-19 2021-06-03 Uniqure Ip B.V. A companion diagnostic to monitor the effects of gene therapy
WO2020104480A1 (en) 2018-11-19 2020-05-28 Uniqure Biopharma B.V. Adeno-associated virus vectors for expressing fviii mimetics and uses thereof
CA3125770A1 (en) * 2019-01-18 2020-07-23 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
KR20210126096A (ko) 2019-02-15 2021-10-19 상가모 테라퓨틱스, 인코포레이티드 재조합 aav를 제조하기 위한 조성물 및 방법
WO2020219897A1 (en) * 2019-04-24 2020-10-29 Biogen Ma Inc. Methods for production of recombinant adeno-associated viruses
SMT202400486T1 (it) 2019-07-15 2025-01-14 Meiragtx Uk Ii Ltd Proteine di capside avv modificate per il trattamento della malattia artritica
WO2021053018A1 (en) 2019-09-16 2021-03-25 Uniqure Ip B.V. Targeting misspliced transcripts in genetic disorders
US20230020565A1 (en) 2019-12-04 2023-01-19 Sangamo Therapeutics, Inc. Novel compositions and methods for producing recombinant aav
KR102932208B1 (ko) * 2019-12-12 2026-03-03 이엠디 밀리포어 코포레이션 정용여과 완충제를 사용한 강화된 바이러스 여과
WO2021154923A2 (en) * 2020-01-29 2021-08-05 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
EP4112735A4 (en) * 2020-02-28 2023-09-06 Asahi Kasei Medical Co., Ltd. METHOD FOR EVALUATING VIRAL CLEARANCE PERFORMANCE
EP4133074A1 (en) 2020-04-07 2023-02-15 uniQure IP B.V. Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof
CN115427561B (zh) 2021-03-09 2024-06-04 辉大(上海)生物科技有限公司 工程化CRISPR/Cas13系统及其用途
CN117120152A (zh) * 2021-03-30 2023-11-24 3M创新有限公司 包含聚砜和聚噁唑啉的中空纤维膜及其制造方法
US20240157306A1 (en) * 2021-03-30 2024-05-16 3M Innovative Properties Company Hollow-fiber membrane and method making thereof
WO2022214635A1 (en) 2021-04-08 2022-10-13 Stichting Vu Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders
CA3219847A1 (en) 2021-06-02 2022-12-08 Sander Jan Hendrik Van Deventer Adeno-associated virus vectors modified to bind high-density lipoprotein
WO2022268811A1 (en) 2021-06-21 2022-12-29 Uniqure Biopharma B.V. Improved lysis procedures
JP2024523445A (ja) 2021-06-21 2024-06-28 ユニキュアー バイオファーマ ビー．ブイ． α－シヌクレインをサイレンシングするための遺伝子構築物及びその使用
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
EP4508216A1 (en) 2022-04-12 2025-02-19 uniQure biopharma B.V. Nucleic acid regulation of snca
EP4508215A1 (en) 2022-04-12 2025-02-19 uniQure biopharma B.V. Novel systems for nucleic acid regulation
US20250223590A1 (en) 2022-04-12 2025-07-10 Uniqure Biopharma B.V. Nucleic acid regulation of ApoE
WO2023198702A1 (en) 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of c9orf72
US20240209324A1 (en) * 2022-12-22 2024-06-27 Cytiva Us Llc Virus separation
EP4698648A1 (en) 2023-04-18 2026-02-25 uniQure biopharma B.V. Gene delivery vehicles comprising rna and antibodies
EP4698555A1 (en) 2023-04-18 2026-02-25 uniQure biopharma B.V. Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs
EP4731267A1 (en) 2023-06-23 2026-04-29 uniQure biopharma B.V. Novel fragile x constructs
EP4774387A1 (en) 2023-09-04 2026-07-15 uniQure biopharma B.V. Novel neurotropic recombinant adeno-associated virus particles
CN122341734A (zh) 2023-10-11 2026-07-03 优尼科生物制药有限公司 重复扩增障碍中msh3的核酸调节
CN122319242A (zh) 2023-10-11 2026-06-30 优尼科生物制药有限公司 亨廷顿蛋白基因的新型核酸调节
WO2025078606A1 (en) 2023-10-11 2025-04-17 Uniqure Biopharma B.V. Further novel systems for nucleic acid regulation
CN122580434A (zh) 2023-11-30 2026-08-14 优尼科生物制药有限公司 用于病毒药物产品的配制品
WO2025219443A1 (en) 2024-04-19 2025-10-23 Uniqure Biopharma B.V. Nucleic acid for a1at regulation
WO2026041782A1 (en) 2024-08-22 2026-02-26 Uniqure Biopharma B.V. Novel raav capsids
US20260061079A1 (en) 2024-08-22 2026-03-05 Uniqure Biopharma B.V. BBB interacting capsids
WO2026087074A1 (en) 2024-10-21 2026-04-30 Invision 20/20 Bardet-biedl syndrome 10 (bbs10) protein gene therapy
WO2026150224A1 (en) 2024-12-30 2026-07-16 MeiraGTx Ocular UK Limited Modified adeno-associated virus (aav) viral capsid proteins and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148143A1 (en) * 2009-06-16 2010-12-23 Genzyme Corporation Improved methods for purification of recombinant aav vectors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP1728800A1 (de) 1994-10-07 2006-12-06 Loyola University Of Chicago Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung
DE19709186C2 (de) 1997-03-06 1999-10-14 Medigene Ag Filtrationsverfahren zur Trennung von Viren
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6593123B1 (en) * 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
WO2003074714A1 (en) 2002-03-05 2003-09-12 Stichting Voor De Technische Wetenschappen Baculovirus expression system
US20050009168A1 (en) * 2003-05-12 2005-01-13 Robbins Joan Marie Methods and apparatus for Adeno associated virus purification
WO2007148971A2 (en) * 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
US20080299545A1 (en) * 2007-03-06 2008-12-04 Shuyuan Zhang Chromatographic methods for assessing adenovirus purity
US20100323429A1 (en) * 2008-04-10 2010-12-23 Yu-Chen Hu Methods for purifying baculovirus
EP2529020B1 (en) * 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
JP6198278B2 (ja) 2011-09-08 2017-09-20 ユニキュアー アイピー ビー．ブイ． Ａａｖ調製物からの混入ウイルスの除去

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148143A1 (en) * 2009-06-16 2010-12-23 Genzyme Corporation Improved methods for purification of recombinant aav vectors

Also Published As

Publication number Publication date
KR101961347B1 (ko) 2019-03-25
MX2014002733A (es) 2014-07-14
US9840694B2 (en) 2017-12-12
KR20140074333A (ko) 2014-06-17
IL231398A (en) 2017-06-29
EP2744895B1 (en) 2015-10-14
IL231398A0 (en) 2014-04-30
US20180100143A1 (en) 2018-04-12
JP6624690B2 (ja) 2019-12-25
WO2013036118A1 (en) 2013-03-14
EP2990477B8 (en) 2018-10-31
DK2744895T3 (en) 2016-01-04
MX349601B (es) 2017-08-04
HUE026579T2 (en) 2016-06-28
ZA201401714B (en) 2015-12-23
SI2744895T1 (sl) 2016-03-31
EP2990477B1 (en) 2018-08-29
US20190218523A1 (en) 2019-07-18
JP2014526246A (ja) 2014-10-06
PT2744895E (pt) 2016-02-08
US20140342434A1 (en) 2014-11-20
HK1220229A1 (en) 2017-04-28
JP2018023365A (ja) 2018-02-15
BR112014005255A2 (pt) 2017-04-04
PL2744895T3 (pl) 2016-04-29
AU2012304993A1 (en) 2014-03-20
EP2990477A1 (en) 2016-03-02
CN103857790A (zh) 2014-06-11
ES2558168T3 (es) 2016-02-02
EA201490583A1 (ru) 2014-07-30
US10253301B2 (en) 2019-04-09
CN103857790B (zh) 2017-09-08
CN107502597A (zh) 2017-12-22
EP3425044A1 (en) 2019-01-09
CA2847604A1 (en) 2013-03-14
EA027511B1 (ru) 2017-08-31
JP6198278B2 (ja) 2017-09-20
EP2744895A1 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
US10253301B2 (en) Removal of contaminating viruses from AAV preparations
JP7595371B2 (ja) トリコプルシア・ニの蛹における組み換えタンパク質の発現
JP6735672B2 (ja) アデノ随伴ウイルス第ｖｉｉｉ因子ベクター
ES2472429T3 (es) Método para la purificación de partículas de adenovirus a partir de cultivos de alta densidad celular
US20030036088A1 (en) Filtration process for separating viruses
US20240287545A1 (en) Improved lysis procedures
Tijssen et al. Parvoviridae. Structure and reproduction of densonucleosis viruses
HK1220229B (en) Removal of contaminating viruses from aav preparations
HK1262994A1 (en) Removal of contaminating viruses from aav preparations
CN115176037A (zh) 病毒清除性能的评价方法
Michalsky et al. Concentration of the baculovirus Autographa californica M nucleopolyhedrovirus (AcMNPV) by ultrafiltration
US20050009168A1 (en) Methods and apparatus for Adeno associated virus purification
Michalsky et al. Purification of the baculovirus Autographa californica M nucleopolyhedrovirus by tangential flow ultrafiltration
Zhou et al. Characterization of two density populations of feline calicivirus particles
JP7588466B2 (ja) パルボウイルスの生産方法
WO2024054983A1 (en) Controlled expression of viral proteins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired